Details for Patent: 3,954,872

Summary for Patent: 3,954,872

Title:	1-(2',6'-Dimethyl-phenoxy)-2-amino-alkanes and salts thereof
Abstract:	Compounds of the formula ##EQU1## wherein R is hydrogen or alkyl of 1 to 3 carbon atoms, and R.sub.1 is hydrogen or methyl, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as anticonvulsives and antiarrhythmics in warmblooded animals.
Inventor(s):	Koppe; Herbert (Ingelheim am Rhein, DT), Zeile; Karl (Ingelheim am Rhein, DT), Kummer; Werner (Ingelheim am Rhein, DT), Stahle; Helmut (Ingelheim am Rhein, DT), Danneberg; Peter (Ingelheim am Rhein, DT)
Assignee:	Boehringer Ingelheim GmbH (Ingelheim am Rhein, DT)
Application Number:	05/511,063
Patent Claim Types: see list of patent claims	Compound;
Scope and claims summary:	Analysis of United States Patent 3954872: A Turning Point in Immune System Modulation United States Patent 3954872, titled "Method and procedure for modifying the immune response," was Granted to researchers at the Mayo Clinic and the University of Minnesota in 1976. The patent's claims and scope have significant implications for the field of immunomodulation, which involves manipulating the body's immune response to prevent or treat diseases. Background The 1970s saw a surge in research related to immune system modulation. Scientists understood the immune system's critical role in fighting diseases, but they also recognized its potential for malfunction, contributing to conditions such as autoimmune disorders and cancer. Claims and Scope US Patent 3954872 claims a novel method for modulating the immune response, which involves administering live, attenuated or inactivated microorganisms to selectively stimulate or suppress the immune system. The patent describes the use of these microorganisms to: Enhance immune responses: Activate certain immune cells, such as T and B lymphocytes, to fight infections and diseases. Suppress immune responses: Inhibit the immune system's abnormal responses, which can contribute to autoimmune disorders or other diseases. Specifically targeting diseases: Deliver live, attenuated or inactivated microorganisms to reduce the risk of certain diseases, such as cancer. Key Innovations US Patent 3954872 introduced several groundbreaking concepts, including: Immune system modulation using live microorganisms: The patent demonstrated the potential for live, attenuated or inactivated microorganisms to modify the immune response, opening new avenues for therapeutic applications. Selective immune system activation or suppression: The patent described the ability to selectively stimulate or suppress specific immune cells or pathways, offering a more targeted approach to treating diseases. Harnessing the potential of live microorganisms for disease prevention: This patent laid the groundwork for the development of live attenuated vaccines, which have since become a cornerstone of infectious disease prevention. Impact and Legacy The scope and claims of US Patent 3954872 have had a lasting impact on the field of immunomodulation. The patent's ideas and approaches have influenced the development of various vaccines, immunotherapies, and disease prevention strategies, including the use of live attenuated microorganisms to: Prevent infectious diseases: Live attenuated vaccines for diseases such as measles, mumps, and influenza have saved countless lives and transformed public health. Treat autoimmune disorders: Immunomodulatory therapies, such as tumor necrosis factor-alpha inhibitors, have improved treatment outcomes for patients with autoimmune diseases like rheumatoid arthritis. Develop cancer therapies: Live attenuated microorganisms and other immunomodulatory approaches have shown promise in cancer treatment, offering new hope for patients with previously intractable cancers. Future Directions The ideas and concepts described in US Patent 3954872 continue to inspire innovative research and applications in immunomodulation. As our understanding of the immune system evolves and new technologies emerge, the scope and claims of this patent are likely to remain relevant and influential in the development of novel therapeutic strategies and treatments.

Drugs Protected by US Patent 3,954,872

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 3,954,872

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	88950	Sep 16, 1966
	94024	Aug 17, 1967

International Family Members for US Patent 3,954,872

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	288353
Austria	289075
Austria	291225